

Ramzi A Ajjan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3178818/publications.pdf>

Version: 2024-02-01

154
papers

8,324
citations

61984

43
h-index

53230

85
g-index

160
all docs

160
docs citations

160
times ranked

10135
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
2	Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2017, 8, 55-73.	2.5	433
3	Review article: Coagulation and fibrinolysis in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 260-273.	2.0	186
4	Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 37-46.	2.8	181
5	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
6	The Pathogenesis of Hashimoto's Thyroiditis: Further Developments in our Understanding. <i>Hormone and Metabolic Research</i> , 2015, 47, 702-710.	1.5	167
7	Use of Flash Glucose-Sensing Technology for 12 Months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 573-586.	2.5	141
8	Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 1.	2.4	110
9	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , 2018, 39, 1078-1085.	2.2	109
10	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
11	Platelet P2Y ₁₂ Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2562-2570.	2.4	105
12	Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. <i>European Heart Journal</i> , 2006, 28, 540-545.	2.2	102
13	Effects of MASP-1 of the Complement System on Activation of Coagulation Factors and Plasma Clot Formation. <i>PLoS ONE</i> , 2012, 7, e35690.	2.5	99
14	The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. <i>Journal of Endocrinology</i> , 1998, 158, 351-358.	2.6	98
15	Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 712-717.	2.4	97
16	Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 34.	6.8	95
17	A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. <i>Diabetologia</i> , 2012, 55, 1103-1113.	6.3	94
18	Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. <i>Clinical and Experimental Immunology</i> , 1996, 105, 523-528.	2.6	93

#	ARTICLE	IF	CITATIONS
19	Cytokines and thyroid function. <i>Advances in Neuroimmunology</i> , 1996, 6, 359-386.	1.8	81
20	Coagulation and atherothrombotic disease. <i>Atherosclerosis</i> , 2006, 186, 240-259.	0.8	81
21	Regulation and tissue distribution of the human sodium iodide symporter gene. <i>Clinical Endocrinology</i> , 1998, 49, 517-523.	2.4	80
22	Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 216-225.	2.0	79
23	Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. <i>Blood</i> , 2013, 122, 134-142.	1.4	79
24	Vitamin D and diabetes mellitus: Causal or casual association?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 227-241.	5.7	74
25	Common variation in the C-terminal region of the fibrinogen β^2 -chain: effects on fibrin structure, fibrinolysis and clot rigidity. <i>Blood</i> , 2008, 111, 643-650.	1.4	71
26	Cytokines in Thyroid Autoimmunity. <i>Autoimmunity</i> , 2003, 36, 351-359.	2.6	68
27	Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	67
28	Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 175-184.	2.0	66
29	Double diabetes: A distinct high-risk group?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2609-2618.	4.4	65
30	Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 278-291.	11.4	60
31	Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1048-1053.	3.4	59
32	Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners. <i>Advances in Therapy</i> , 2019, 36, 579-596.	2.9	58
33	Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 147-158.	2.0	57
34	How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-27-S-36.	4.4	56
35	Clot Architecture Is Altered in Abdominal Aortic Aneurysms and Correlates With Aneurysm Size. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 3004-3010.	2.4	55
36	The Modulation of the Human Sodium Iodide Symporter Activity by Graves' Disease Sera. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1217-1221.	3.6	51

#	ARTICLE	IF	CITATIONS
37	Gender-Specific Alterations in Fibrin Structure Function in Type 2 Diabetes: Associations with Cardiometabolic and Vascular Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2282-E2287.	3.6	51
38	Detection of IL-12, IL-13, and IL-15 Messenger Ribonucleic Acid in the Thyroid of Patients with Autoimmune Thyroid Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 666-669.	3.6	49
39	A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease. <i>Clinical Endocrinology</i> , 1998, 49, 577-581.	2.4	49
40	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1142-1150.	3.4	49
41	Thyroid Dysfunction and Fibrin Network Structure: A Mechanism for Increased Thrombotic Risk in Hyperthyroid Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1463-1473.	3.6	47
42	The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. <i>BMC Endocrine Disorders</i> , 2015, 15, 14.	2.2	47
43	Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 385-395.	2.0	47
44	An observational study of patient characteristics and mortality following hypoglycemia in the community. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000094.	2.8	45
45	Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2625-2633.	8.6	44
46	Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. <i>Diabetologia</i> , 2014, 57, 1737-1741.	6.3	43
47	Techniques to quantify TSH receptor antibodies. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 461-468.	2.8	42
48	Analysis of the T-cell receptor Valpha repertoire and cytokine gene expression in Sjogren's syndrome. <i>Rheumatology</i> , 1998, 37, 179-185.	1.9	40
49	New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 237-245.	3.3	40
50	Total plasma magnesium, zinc, copper and selenium concentrations in type-I and type-II diabetes. <i>BioMetals</i> , 2019, 32, 123-138.	4.1	38
51	PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3170.	4.1	38
52	The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0168549.	2.5	35
53	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. <i>PLoS ONE</i> , 2013, 8, e71150.	2.5	32
54	Role of complement in diabetes. <i>Molecular Immunology</i> , 2019, 114, 270-277.	2.2	31

#	ARTICLE	IF	CITATIONS
55	Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. <i>Cardiovascular Diabetology</i> , 2020, 19, 3.	6.8	31
56	The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 883-891.	1.5	30
57	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259.	2.2	29
58	The cardiovascular safety of rosiglitazone. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 367-376.	2.4	28
59	Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. <i>Clinical Endocrinology</i> , 2013, 79, 252-258.	2.4	28
60	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 412-422.	3.4	27
61	Vascular risk in obesity: Facts, misconceptions and the unknown. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 2-13.	2.0	26
62	Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. <i>Platelets</i> , 2019, 30, 148-157.	2.3	25
63	Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 3-12.	2.0	25
64	Coronary artery disease-associated genetic variants and biomarkers of inflammation. <i>PLoS ONE</i> , 2017, 12, e0180365.	2.5	25
65	Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: Beyond glycated haemoglobin. <i>Diabetic Medicine</i> , 2021, 38, e14529.	2.3	24
66	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 622-631.	3.4	23
67	Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 211-219.	2.0	23
68	Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000611.	2.8	23
69	Glucokinase MODY and Implications for Treatment Goals of Common Forms of Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 559.	4.2	22
70	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	3.4	21
71	Cardiovascular disease and heritability of the prothrombotic state. <i>Blood Reviews</i> , 2009, 23, 67-78.	5.7	20
72	The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 189.	3.5	20

#	ARTICLE	IF	CITATIONS
73	<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	2.4	20
74	Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. Cardiovascular Diabetology, 2020, 19, 127.	6.8	20
75	A Kinetic Model for Glucose Levels and Hemoglobin A1c Provides a Novel Tool for Individualized Diabetes Management. Journal of Diabetes Science and Technology, 2021, 15, 294-302.	2.2	20
76	Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. Lancet, The, 2015, 385, S57.	13.7	19
77	Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?. Diabetes Therapy, 2018, 9, 1831-1851.	2.5	19
78	Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. Drugs, 2021, 81, 1365-1371.	10.9	19
79	Supported self-management for adults with type 2 diabetes and a learning disability (OK-Diabetes): study protocol for a randomised controlled feasibility trial. Trials, 2015, 16, 342.	1.6	18
80	Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection. Diabetes and Vascular Disease Research, 2020, 17, 147916412092058.	2.0	18
81	Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. Blood, 2019, 133, 1233-1244.	1.4	17
82	Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. Thrombosis and Haemostasis, 2020, 120, 075-082.	3.4	17
83	Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. International Journal of Molecular Sciences, 2020, 21, 2897.	4.1	17
84	Lipidomic profiling of plasma free fatty acids in type-1 diabetes highlights specific changes in lipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158823.	2.4	17
85	Albumin-mediated alteration of plasma zinc speciation by fatty acids modulates blood clotting in type-2 diabetes. Chemical Science, 2021, 12, 4079-4093.	7.4	16
86	A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3316-3323.	3.6	15
87	An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial. Diabetes and Vascular Disease Research, 2017, 14, 336-344.	2.0	15
88	Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes. Cardiovascular Diabetology, 2018, 17, 35.	6.8	15
89	Fibrinolysis in Acute and Chronic Cardiovascular Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 490-505.	2.7	15
90	Exploring the facilitators, barriers, and strategies for self-management in adults living with severe mental illness, with and without long-term conditions: A qualitative evidence synthesis. PLoS ONE, 2021, 16, e0258937.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 795-801.	3.8	14
92	Hypoglycaemia, thrombosis and vascular events in diabetes. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1099-1101.	1.5	14
93	Personal Glycation Factors and Calculated Hemoglobin A1c for Diabetes Management: Real-World Data from the Diabetes Prospective Follow-up (DPV) Registry. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 452-459.	4.4	13
94	Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 243-252.	3.4	13
95	Fibrinogen $\hat{\pm}$ C-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis. <i>ELife</i> , 2021, 10, .	6.0	13
96	The role of lectin-like oxidised low-density lipoprotein receptor-1 in vascular pathology. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 410-418.	2.0	12
97	Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2019, 26, 347-357.	2.1	12
98	Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 745-747.	2.2	12
99	Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6916.	4.1	12
100	Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: A cross-sectional pilot study. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095232.	2.0	11
101	Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?. <i>Current Pharmaceutical Design</i> , 2021, 27, 1061-1067.	1.9	11
102	Addressing shortfalls of laboratory HbA1c using a model that incorporates red cell lifespan. <i>ELife</i> , 2021, 10, .	6.0	11
103	Managing with Learning Disability and Diabetes: OK-Diabetes â€œ a case-finding study and feasibility randomised controlled trial. <i>Health Technology Assessment</i> , 2018, 22, 1-328.	2.8	11
104	Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 1047-1059.	1.5	10
105	Characterizing adults with Type 2 diabetes mellitus and intellectual disability: outcomes of a caseâ€œfinding study. <i>Diabetic Medicine</i> , 2018, 35, 352-359.	2.3	10
106	Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologistsâ€™ attitudes and practice. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 194-196.	3.0	10
107	Elimination of fibrin $\hat{\gamma}$ 3-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2103226118.	7.1	10
108	Prenatal and Postpartum Maternal Iodide Intake from Diet and Supplements, Urinary Iodine and Thyroid Hormone Concentrations in a Region of the United Kingdom with Mild-to-Moderate Iodine Deficiency. <i>Nutrients</i> , 2021, 13, 230.	4.1	10

#	ARTICLE	IF	CITATIONS
109	Diabetes mellitus and perioperative outcomes: a scoping review of the literature. <i>British Journal of Anaesthesia</i> , 2022, 128, 817-828.	3.4	10
110	<sc>IL</sc>14 and <sc>IL</sc>16 are expressed in the thyroid of patients with either Gravesâ€™ disease or Hashimoto's thyroiditis. <i>Clinical Endocrinology</i> , 2015, 83, 726-732.	2.4	9
111	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. <i>Haematologica</i> , 2021, 106, 1616-1623.	3.5	9
112	Interindividual variability in average <sc>glucoseâ€glycated haemoglobin</sc> relationship in type 1 diabetes and implications for clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1779-1787.	4.4	9
113	Insulin Resistance and Cardiovascular Risk Marker Evaluation in Morbid Obesity 12 Months After Bariatric Surgery Compared to Weight-Matched Controls. <i>Obesity Surgery</i> , 2014, 24, 349-358.	2.1	8
114	Accurate prediction of HbA1c by continuous glucose monitoring using a kinetic model with patient-specific parameters for red blood cell lifespan and glucose uptake. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110137.	2.0	8
115	Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention. <i>Cardiovascular Diabetology</i> , 2021, 20, 18.	6.8	8
116	Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1113-1121.	3.1	7
117	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1248-1256.	3.4	7
118	Improving outcome prediction in individuals with colorectal cancer and diabetes by accurate assessment of vascular complications: Implications for clinical practice. <i>European Journal of Surgical Oncology</i> , 2021, 47, 999-1004.	1.0	7
119	Estimated glucose disposal rate as a candidate biomarker for thrombotic biomarkers in T1D: a pooled analysis. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2417-2426.	3.3	7
120	Effect of hypoglycaemia on thrombosis and inflammation in patients with type 2 diabetes. <i>Lancet</i> , The, 2014, 383, S35.	13.7	6
121	Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12537.	4.1	6
122	Use of continuous glucose monitoring trend arrows in the younger population with type 1 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110621.	2.0	6
123	Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 623-627.	1.5	5
124	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. <i>Thrombosis Research</i> , 2014, 133, 1161-1163.	1.7	5
125	The Relationship between Primary Hyperparathyroidism and Thrombotic Events: Report of Three Cases and a Review of Potential Mechanisms. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2018, 12, 175-180.	0.3	4
126	Total plasma magnesium, zinc, copper and selenium concentrations in obese patients before and after bariatric surgery. <i>BioMetals</i> , 2023, 36, 241-253.	4.1	4

#	ARTICLE	IF	CITATIONS
127	Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study. <i>Diabetes and Vascular Disease Research</i> , 2022, 19, 147916412211032.	2.0	4
128	New insights into antibody-mediated hyperthyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 67-81.	2.4	3
129	Raising awareness of Graves' orbitopathy with early warning cards. <i>Clinical Endocrinology</i> , 2017, 87, 853-859.	2.4	3
130	B β 2Arg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 295-302.	3.4	3
131	Development of a supported self-management intervention for adults with type 2 diabetes and a learning disability. <i>Pilot and Feasibility Studies</i> , 2018, 4, 106.	1.2	3
132	Associations Between Erythrocyte Membrane Fatty Acid Compositions and Biomarkers of Vascular Health in Adults With Type 1 Diabetes With and Without Insulin Resistance: A Cross-Sectional Analysis. <i>Canadian Journal of Diabetes</i> , 2022, 46, 111-117.	0.8	3
133	Thyroid Autoantibody Measurement. <i>Growth Hormone</i> , 2010, , 109-124.	0.2	3
134	The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes – A Cross-over Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 26.	3.5	2
135	Glucose monitoring in diabetes: from clinical studies to real-world practice. <i>Practical Diabetes</i> , 2019, 36, 57-62.	0.3	2
136	Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095793.	2.0	2
137	Antiplatelet therapies in diabetes. <i>Diabetic Medicine</i> , 2020, 37, 726-734.	2.3	2
138	Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries. <i>The Cochrane Library</i> , 2021, 2021, CD013281.	2.8	2
139	Exploring determinants of self-management in adults with severe mental illness: a qualitative evidence synthesis. <i>BJPsych Open</i> , 2021, 7, S13-S13.	0.7	2
140	Application of Machine Learning to Assess Interindividual Variability in Rapid-Acting Insulin Responses After Subcutaneous Injection in People With Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2022, 46, 225-232.e2.	0.8	2
141	733-P: Postprandial Glucose Variability in People with Type 1 Diabetes Is Individual and Impacted by Physiological and Clinical Parameters. <i>Diabetes</i> , 2020, 69, 733-P.	0.6	2
142	The relative contribution of diurnal and nocturnal glucose exposures to HbA1c in type 1 diabetes males: a pooled analysis. <i>Journal of Diabetes and Metabolic Disorders</i> , 0, , 1.	1.9	2
143	A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. <i>Cardiovascular Diabetology</i> , 2021, 20, 238.	6.8	2
144	Thyroid Autoantibodies. <i>Endocrinology</i> , 2018, , 57-87.	0.1	1

#	ARTICLE	IF	CITATIONS
145	Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial. <i>Diabetes and Vascular Disease Research</i> , 2022, 19, 147916412110674.	2.0	1
146	Purification and Analysis of Circulating Lipid Particles. <i>Methods in Molecular Biology</i> , 2022, 2419, 193-212.	0.9	1
147	Non-Traditional Pathways for Platelet Pathophysiology in Diabetes: Implications for Future Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4973.	4.1	1
148	Irish endocrine society: 23rd annual meeting. <i>Irish Journal of Medical Science</i> , 1998, 167, 2-10.	1.5	0
149	Coronary thrombosis in diabetes: Are we doing enough?. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 445-448.	2.0	0
150	Primary vascular prevention: The end of the road for aspirin?. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 475-476.	2.0	0
151	Thyroid Autoantibodies. <i>Endocrinology</i> , 2016, , 1-31.	0.1	0
152	Prothrombotic fibrin network characteristics in patients with acromegaly: a novel mechanism for vascular complications. <i>European Journal of Endocrinology</i> , 2020, 182, 511-521.	3.7	0
153	Maturity onset diabetes of the young and fibrin-related thrombosis risk. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412096304.	2.0	0
154	Affinity purification of fibrinogen using an Affimer column. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130115.	2.4	0